Faron Pharmaceuticals Oy (LON:FARN) Shares Up 16.7% – Still a Buy?

Shares of Faron Pharmaceuticals Oy (LON:FARN) shot up 16.7% during trading on Wednesday . The stock traded as high as GBX 61.50 and last traded at GBX 59.50. 97,510 shares were traded during mid-day trading, a decline of 48% from the average session volume of 186,179 shares. The stock had previously closed at GBX 51.

Faron Pharmaceuticals Oy Price Performance

The company has a market capitalization of £62.02 million, a price-to-earnings ratio of -2.01 and a beta of 0.36. The company has a fifty day simple moving average of GBX 132.55 and a two-hundred day simple moving average of GBX 169.23. The company has a debt-to-equity ratio of -133.35, a quick ratio of 1.09 and a current ratio of 0.84.

Insiders Place Their Bets

In other Faron Pharmaceuticals Oy news, insider Jurriaan Dekkers sold 4,000 shares of the firm’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of GBX 182, for a total value of £7,280. Company insiders own 4.05% of the company’s stock.

Faron Pharmaceuticals Oy Company Profile

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.